MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
University of Houston · The University of Texas Medical Branch at Galveston · +1 more institution
Abstract
Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the development of cancer therapy. MDM2's activities extend from carcinogenesis to immunity to the response to various cancer therapies. Since the report of the first MDM2 inhibitor more than 30 years ago, various approaches to inhibit MDM2 have been attempted, with hundreds of small-molecule inhibitors evaluated in preclinical studies and numerous molecules tested in clinical trials. Although many MDM2 inhibitors and degraders have been evaluated in clinical trials, there is currently no Food and Drug Administration (FDA)-approved MDM2 inhibitor on the market. Nevertheless, there are several current clinical trials of…
Citation impact
- FWCI
- 27.63
- Percentile
- 100%
- References
- 343
Authors
10- WWWei WangCorresponding
University of Houston, The University of Texas Medical Branch at Galveston
- NANajah Albadari
University of Tennessee Health Science Center, The University of Texas Medical Branch at Galveston
- YDYi Du
University of Houston, The University of Texas Medical Branch at Galveston
- JFJosef F. Fowler
University of Houston, The University of Texas Medical Branch at Galveston
- HTHannah T. Sang
University of Houston, The University of Texas Medical Branch at Galveston
Topics & keywords
- Mdm2
- Clinical trial
- Cancer
- Medicine
- Cancer research
- Bioinformatics
- Biology
- Internal medicine
- Good health and well-being
Funding
- CPCancer Prevention and Research Institute of TexasAward: RR150104
- ASAmerican Society for Pharmacology and Experimental Therapeutics
- UOUniversity of Hail
- NINational Institutes of HealthAwards: R01CA240447, 1R01CA241600-01, U24CA228550, R01CA214019, 1R01DK115445-01A1
- NCNational Cancer InstituteAwards: R01CA214019, R01CA240447
- NINational Institute of Diabetes and Digestive and Kidney Diseases